Compare Gilead Sciences, Inc. (GILD) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs US Bancorp — how do they compare? Gilead Sciences, Inc. trades at $147.1 (market cap $182.09B), while US Bancorp trades at $57.3 (market cap $87.52B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× US Bancorp's market cap, and US Bancorp pays the higher dividend (3.85%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and US Bancorp for 97 Days on average.
| GILD | USB | |
|---|---|---|
Market Cap | $182.09B | $87.52B |
Volume | 4,960,247 | 9,184,647 |
Sector | Health | Financials |
52-Week High | $155.80 | $65.42 |
52-Week Low | $116.74 | $45.28 |
Typical Hold Time | 111 Days | 97 Days |
Enterprise Value | $205.15B | $117.01B |
Dividend Yield | 2.23% | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
U.S. Bancorp (USB) trades at $57.03, down 0.45% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.35 exceeding expectations by 5.5%. Revenue growth accelerated to $28.54B in 2025 with net income margin improving to 27.61%. Analyst consensus remains positive with 51% buy ratings and $69.94 price target representing 23% upside potential.
USB presents a value opportunity with attractive valuation multiples (P/E 11.21, P/B 1.44) and dividend yield of 3.8%. Near-term risks include technical weakness and regulatory uncertainties, but strong fee revenue growth and capital markets performance support the bullish fundamental case. The stock offers income appeal with sustainable dividend growth and clean loan portfolio positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
